Memorial Sloan-Kettering’s Bach Balks At Drug Pricing
This article was originally published in The Pink Sheet Daily
Peter Bach slammed the industry over high drug prices and practices such as rebating, which he said confound open debate about drug cost and benefit, during a panel discussion at the BIO CEO & Investor conference.
You may also be interested in...
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.